U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H24N6O5S2
Molecular Weight 480.564
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CEFEPIME

SMILES

C[N+]1(CCCC1)CC2=C(C(=O)[O-])N3C(=O)[C@]([H])([C@@]3([H])SC2)N=C(/C(=N\OC)/c4csc(=N)[nH]4)O

InChI

InChIKey=HVFLCNVBZFFHBT-ZKDACBOMSA-N
InChI=1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment:: https://www.drugs.com/cdi/cefepime.html

Cefepime is a fourth-generation cephalosporin antibiotic, which was developed in 1994. Cefepime has a broad spectrum in vitro activity that encompasses a wide range of Gram-positive and Gram-negative bacteria. Within bacterial cells, the molecular targets of cefepime are the penicillin binding proteins (PBP). It is FDA approved for the treatment of pneumonia, febrile neutropenia, uncomplicated UTI, uncomplicated skin infection and complicated intraabdominal infections. Common adverse reactions include rash, hypophosphatemia, diarrhea. Cefepime is metabolized to N-methylpyrrolidine (NMP) which is rapidly converted to the N-oxide (NMP-N-oxide). Urinary recovery of unchanged cefepime accounts for approximately 85% of the administered dose. Less than 1% of the administered dose is recovered from urine as NMP, 6.8% as NMP-N-oxide, and 2.5% as an epimer of cefepime. Because renal excretion is a significant pathway of elimination, patients with renal dysfunction and patients undergoing hemodialysis require dosage adjustment.

CNS Activity

Curator's Comment:: It has been confirmed that the concentration of cefepime in cerebrospinal fluid (CSF) could reach the 10% of its concentration in plasma, exceeding the inhibitory concentration to 90% of organisms (MIC(90)) for common bacteria. However, the blood-brain barrier (BBB) penetration ability of cefepime is still unclear

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
MAXIPIME

Approved Use

Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes. Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis. (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

821923200000
Curative
MAXIPIME

Approved Use

Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes. Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis. (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

821923200000
Curative
MAXIPIME

Approved Use

Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes. Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis. (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

821923200000
Curative
MAXIPIME

Approved Use

Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes. Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis. (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

821923200000
Curative
MAXIPIME

Approved Use

Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes. Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis. (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

821923200000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
29.6 μg/mL
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFEPIME HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
81.7 μg/mL
1 g single, intravenous
dose: 1 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFEPIME HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
57.5 μg/mL
2 g single, intramuscular
dose: 2 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFEPIME HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
163.9 μg/mL
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFEPIME HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
13.9 μg/mL
500 mg single, intramuscular
dose: 500 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFEPIME HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
39.1 μg/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFEPIME HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
137 μg × h/mL
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFEPIME HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
148.5 μg × h/mL
1 g single, intravenous
dose: 1 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFEPIME HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
262 μg × h/mL
2 g single, intramuscular
dose: 2 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFEPIME HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
284.8 μg × h/mL
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFEPIME HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
60 μg × h/mL
500 mg single, intramuscular
dose: 500 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFEPIME HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
70.8 μg × h/mL
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFEPIME HYDROCHLORIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
unknown, unknown
CEFEPIME HYDROCHLORIDE serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
80%
unknown, unknown
CEFEPIME HYDROCHLORIDE serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 g 3 times / day multiple, intravenous
Highest studied dose|Recommended
dose: 2 g 3 times / day
route: intravenous
experiment_type: multiple
dose_type: Highest studied dose|Recommended
co-adm with
    data_source:
    https://pubmed.ncbi.nlm.nih.gov/31549737
    unhealthy, 53.2 years
    population: unhealthy
    age: 53.2 years
    sex: M+F
    food_status:
    n:
    data_source:
    https://pubmed.ncbi.nlm.nih.gov/31549737
    1 g 2 times / day multiple, intravenous|intramuscular
    dose: 1 g 2 times / day
    route: intravenous|intramuscular
    experiment_type: multiple
    dose_type:
    co-adm with
      data_source:
      https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf
      unhealthy
      population: unhealthy
      age:
      sex:
      food_status:
      n:
      data_source:
      https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf
      Disc. AE: Rash...
      AEs leading to
      discontinuation/dose reduction:​
      Rash (2 times / day)

      data_source:
      https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf
      2 g 2 times / day multiple, intravenous|intramuscular
      dose: 2 g 2 times / day
      route: intravenous|intramuscular
      experiment_type: multiple
      dose_type:
      co-adm with
        data_source:
        https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf
        unhealthy
        population: unhealthy
        age:
        sex:
        food_status:
        n:
        data_source:
        https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf
        Disc. AE: Rash...
        AEs leading to
        discontinuation/dose reduction:​
        Rash (2 times / day)

        data_source:
        https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf
        500 mg 2 times / day multiple, intravenous|intramuscular
        dose: 500 mg 2 times / day
        route: intravenous|intramuscular
        experiment_type: multiple
        dose_type:
        co-adm with
          data_source:
          https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf
          unhealthy
          population: unhealthy
          age:
          sex:
          food_status:
          n:
          data_source:
          https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf
          Disc. AE: Rash...
          AEs leading to
          discontinuation/dose reduction:​
          Rash (2 times / day)

          data_source:
          https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf
          AEs

          AEs

          AESignificanceDosePopulation
          Rash 1.1%
          Disc. AE
          1 g 2 times / day multiple, intravenous|intramuscular
          dose: 1 g 2 times / day
          route: intravenous|intramuscular
          experiment_type: multiple
          dose_type:
          co-adm with
            data_source:
            https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf
            unhealthy
            Rash 2%
            Disc. AE
            2 g 2 times / day multiple, intravenous|intramuscular
            dose: 2 g 2 times / day
            route: intravenous|intramuscular
            experiment_type: multiple
            dose_type:
            co-adm with
              data_source:
              https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf
              unhealthy
              Rash 0.8%
              Disc. AE
              500 mg 2 times / day multiple, intravenous|intramuscular
              dose: 500 mg 2 times / day
              route: intravenous|intramuscular
              experiment_type: multiple
              dose_type:
              co-adm with
                data_source:
                https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf
                unhealthy
                PubMed

                PubMed

                TitleDatePubMed
                Efficacy of cefepime in a Staphylococcus aureus endocarditis rat model.
                1993 Nov
                Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure.
                2001 Aug
                Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
                2001 Nov
                Metronidazole-induced encephalopathy in a uremic patient: a case report.
                2001 Sep
                Reversible metronidazole-induced lesions of the cerebellar dentate nuclei.
                2002 Jan 3
                Effects of some antibiotics on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro and in vivo study.
                2004 Aug
                Invasive fungal infection of the maxilla following dental extractions in a patient with chronic obstructive pulmonary disease.
                2006 Mar
                Encephalopathy with myoclonic jerks resulting from ceftazidime therapy: an under-recognized potential side-effect when treating febrile neutropenia.
                2007 Feb
                Fixed dose combination of cefepime plus amikacin prevent oxidative stress in liver of Mus musculus mice.
                2008 Sep
                Probable trimethoprim/sulfamethoxazole-induced higher-level gait disorder and nocturnal delirium in an elderly man.
                2009 Jan
                Cefepime-related encephalopathy in peritoneal dialysis patients.
                2011 Feb
                Investigation of the effects of some drugs and phenolic compounds on human dihydrofolate reductase activity.
                2015 Mar
                Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
                2015 May 18
                Patents

                Sample Use Guides

                Moderate to Severe Pneumonia: 1 to 2 g IV, every 8 to 12 hours; 10 days.
                Route of Administration: Other
                In Vitro Use Guide
                Cefepime showed excellent activity against E. coli and K. pneumoniae, inhibiting 90% of these isolates at 0.12 mg/l. 84 isolates of methicillin-susceptible S. aureus were inhibited by 8 mg/l of cefepime.
                Name Type Language
                CEFEPIME
                INN   MI   USAN   VANDF   WHO-DD  
                INN   USAN  
                Official Name English
                1-(((6R,7R)-7-(2-(2-AMINO-4-THIAZOLYL)GLYOXYLAMIDO)-2-CARBOXY-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-EN-3-YL)METHYL)-1-METHYLPYRROLIDINIUM HYDROXIDE, INNER SALT, 7(SUP 2)-(Z)-(O-METHYLOXIME)
                Common Name English
                VNRX-5022
                Code English
                CEFEPIME [MI]
                Common Name English
                CEFEPIME [INN]
                Common Name English
                CEFEPIME [USAN]
                Common Name English
                PYRROLIDINIUM, 1-((7-(((2-AMINO-4-THIAZOLYL)(METHOXYIMINO)ACETYL)AMINO)-2-CARBOXY-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-EN-3-YL)METHYL)-1-METHYL-, HYDROXIDE, INNER SALT, (6R-(6.ALPHA.,7.BETA.(Z)))-
                Common Name English
                CEFEPIME [VANDF]
                Common Name English
                CEFEPIME [WHO-DD]
                Common Name English
                J01DE01
                Code English
                BMY-28142
                Code English
                Classification Tree Code System Code
                NDF-RT N0000011161
                Created by admin on Sat Jun 26 11:33:38 UTC 2021 , Edited by admin on Sat Jun 26 11:33:38 UTC 2021
                NDF-RT N0000011161
                Created by admin on Sat Jun 26 11:33:38 UTC 2021 , Edited by admin on Sat Jun 26 11:33:38 UTC 2021
                NDF-RT N0000011161
                Created by admin on Sat Jun 26 11:33:37 UTC 2021 , Edited by admin on Sat Jun 26 11:33:37 UTC 2021
                WHO-VATC QJ01DE01
                Created by admin on Sat Jun 26 11:33:38 UTC 2021 , Edited by admin on Sat Jun 26 11:33:38 UTC 2021
                WHO-ATC J01DE01
                Created by admin on Sat Jun 26 11:33:37 UTC 2021 , Edited by admin on Sat Jun 26 11:33:37 UTC 2021
                NCI_THESAURUS C357
                Created by admin on Sat Jun 26 11:33:37 UTC 2021 , Edited by admin on Sat Jun 26 11:33:37 UTC 2021
                NDF-RT N0000011161
                Created by admin on Sat Jun 26 11:33:38 UTC 2021 , Edited by admin on Sat Jun 26 11:33:38 UTC 2021
                NDF-RT N0000175488
                Created by admin on Sat Jun 26 11:33:38 UTC 2021 , Edited by admin on Sat Jun 26 11:33:38 UTC 2021
                NDF-RT N0000011161
                Created by admin on Sat Jun 26 11:33:38 UTC 2021 , Edited by admin on Sat Jun 26 11:33:38 UTC 2021
                NDF-RT N0000011161
                Created by admin on Sat Jun 26 11:33:38 UTC 2021 , Edited by admin on Sat Jun 26 11:33:38 UTC 2021
                LIVERTOX 163
                Created by admin on Sat Jun 26 11:33:37 UTC 2021 , Edited by admin on Sat Jun 26 11:33:37 UTC 2021
                NDF-RT N0000011161
                Created by admin on Sat Jun 26 11:33:37 UTC 2021 , Edited by admin on Sat Jun 26 11:33:37 UTC 2021
                NDF-RT N0000011161
                Created by admin on Sat Jun 26 11:33:37 UTC 2021 , Edited by admin on Sat Jun 26 11:33:37 UTC 2021
                NDF-RT N0000011161
                Created by admin on Sat Jun 26 11:33:38 UTC 2021 , Edited by admin on Sat Jun 26 11:33:38 UTC 2021
                WHO-ATC J01RA06
                Created by admin on Sat Jun 26 11:33:37 UTC 2021 , Edited by admin on Sat Jun 26 11:33:37 UTC 2021
                NDF-RT N0000011161
                Created by admin on Sat Jun 26 11:33:38 UTC 2021 , Edited by admin on Sat Jun 26 11:33:38 UTC 2021
                NDF-RT N0000011161
                Created by admin on Sat Jun 26 11:33:38 UTC 2021 , Edited by admin on Sat Jun 26 11:33:38 UTC 2021
                NDF-RT N0000011161
                Created by admin on Sat Jun 26 11:33:38 UTC 2021 , Edited by admin on Sat Jun 26 11:33:38 UTC 2021
                Code System Code Type Description
                LACTMED
                Cefepime
                Created by admin on Sat Jun 26 11:33:37 UTC 2021 , Edited by admin on Sat Jun 26 11:33:37 UTC 2021
                PRIMARY
                DRUG CENTRAL
                535
                Created by admin on Sat Jun 26 11:33:37 UTC 2021 , Edited by admin on Sat Jun 26 11:33:37 UTC 2021
                PRIMARY
                MERCK INDEX
                M3193
                Created by admin on Sat Jun 26 11:33:37 UTC 2021 , Edited by admin on Sat Jun 26 11:33:37 UTC 2021
                PRIMARY Merck Index
                FDA UNII
                807PW4VQE3
                Created by admin on Sat Jun 26 11:33:37 UTC 2021 , Edited by admin on Sat Jun 26 11:33:37 UTC 2021
                PRIMARY
                CAS
                88040-23-7
                Created by admin on Sat Jun 26 11:33:37 UTC 2021 , Edited by admin on Sat Jun 26 11:33:37 UTC 2021
                PRIMARY
                PUBCHEM
                5479537
                Created by admin on Sat Jun 26 11:33:38 UTC 2021 , Edited by admin on Sat Jun 26 11:33:38 UTC 2021
                PRIMARY
                NCI_THESAURUS
                C65294
                Created by admin on Sat Jun 26 11:33:37 UTC 2021 , Edited by admin on Sat Jun 26 11:33:37 UTC 2021
                PRIMARY
                RXCUI
                20481
                Created by admin on Sat Jun 26 11:33:38 UTC 2021 , Edited by admin on Sat Jun 26 11:33:38 UTC 2021
                PRIMARY RxNorm
                MESH
                C043266
                Created by admin on Sat Jun 26 11:33:37 UTC 2021 , Edited by admin on Sat Jun 26 11:33:37 UTC 2021
                PRIMARY
                INN
                6092
                Created by admin on Sat Jun 26 11:33:37 UTC 2021 , Edited by admin on Sat Jun 26 11:33:37 UTC 2021
                PRIMARY
                ChEMBL
                CHEMBL186
                Created by admin on Sat Jun 26 11:33:37 UTC 2021 , Edited by admin on Sat Jun 26 11:33:37 UTC 2021
                PRIMARY
                WIKIPEDIA
                CEFEPIME
                Created by admin on Sat Jun 26 11:33:38 UTC 2021 , Edited by admin on Sat Jun 26 11:33:38 UTC 2021
                PRIMARY
                DRUG BANK
                DB01413
                Created by admin on Sat Jun 26 11:33:37 UTC 2021 , Edited by admin on Sat Jun 26 11:33:37 UTC 2021
                PRIMARY
                EVMPD
                SUB07390MIG
                Created by admin on Sat Jun 26 11:33:37 UTC 2021 , Edited by admin on Sat Jun 26 11:33:37 UTC 2021
                PRIMARY